A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

Inclusion Criteria

• •Body mass index of 18 to 33 kg/m2 at the time of consent.
• •Meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for MDD based on the Structured Clinical Interview for DSM-5.
• •Current major depressive episode of at least 6 weeks to less than 24 months in duration at Screening (Visit 1 ).
• •Meets the following disease activity criteria mentioned in the protocol.
• •Requires antidepressant therapy (ADT) per the investigator's opinion or, if currently taking ADT, must be able to safely discontinue ADT at least 7 days prior to the first dose of study drug at Baseline (Visit 2).